Hideaki Isago
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hideaki Isago has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Akihisa Mitani
Department of Respiratory Medicine, Graduate School of Medicine The University of Tokyo Tokyo Japan
9 shared publications - Minako Saito
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan
8 shared publications - Taro Ishimori
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan
8 shared publications - Takahide Nagase
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
7 shared publications - Hiroyuki Tamiya
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan
6 shared publications - Taisuke Jo
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-0033, Japan
6 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 51
Application of blood rheology to develop hemolysis-free serum extraction sampling method for small-volume blood
- 22 July 2026
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 51
Open AccessApplication of blood rheology to develop hemolysis-free serum extraction sampling method for small-volume blood
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 329 (2) , L200-L213
Sirtuin 3 deficiency exacerbates emphysema and lung inflammation in a murine model of chronic obstructive pulmonary disease
Our study is the first to elucidate the protective role of SIRT3 in the pathogenesis of COPD by modulating inflammatory responses and apoptosis. We have demonstrated that SIRT3 knockout mice spontaneously develop emphysema, and SIRT3 overexpression reduced elastase and LPS-induced emphysematous changes. In vitro studies have shown that SIRT3 deficiency leads to increased inflammation, oxidative stress, and apoptosis in airway and alveolar epithelium, contributing to the formation and exacerbation of emphysema.
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 329 (2) , L200-L213
Sirtuin 3 deficiency exacerbates emphysema and lung inflammation in a murine model of chronic obstructive pulmonary disease
Our study is the first to elucidate the protective role of SIRT3 in the pathogenesis of COPD by modulating inflammatory responses and apoptosis. We have demonstrated that SIRT3 knockout mice spontaneously develop emphysema, and SIRT3 overexpression reduced elastase and LPS-induced emphysematous changes. In vitro studies have shown that SIRT3 deficiency leads to increased inflammation, oxidative stress, and apoptosis in airway and alveolar epithelium, contributing to the formation and exacerbation of emphysema.
- Open Access
- 18 January 2025
- Published by Elsevier in Lung Cancer
- Vol. 200, 108099
Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database
- 18 January 2025
- Published by Elsevier in Lung Cancer
- Vol. 200, 108099
Open AccessClinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database
- Open Access
- 25 December 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 746, 151234
Modulating lysophospholipids with Paraoxonase-1: Exploring its impact on inflammatory responses and immune reactions
- 25 December 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 746, 151234
Open AccessModulating lysophospholipids with Paraoxonase-1: Exploring its impact on inflammatory responses and immune reactions
- Open Access
- 1 September 2024
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 31 (9) , 1249-1259
The Association between Dyslipidemia and Pulmonary Diseases
Dyslipidemia is one of the most common diseases worldwide. As a component of metabolic syndrome, the prevalence and mechanism by which dyslipidemia promotes cardiovascular diseases has been well studied, although the relationship between pulmonary diseases is not well understood. Because the lung is a respiratory organ with a large surface area and is exposed to the environment outside the body, it continuously inhales various substances. As a result, pulmonary diseases have a vast diversity, including chronic inflammatory diseases, allergic diseases, cancers, and infectious diseases. Recently, growing evidence has suggested that dyslipidemia plays a role in the pathogenesis and prognosis of various pulmonary diseases. We herein review the current understanding of the relationship between dyslipidemia and pulmonary diseases, including chronic obstructive pulmonary diseases, asthma, and lung cancer, and infectious pulmonary diseases, including community-acquired pneumonia, tuberculosis, nontuberculous mycobacterial pulmonary disease, and COVID-19. In addition, we focus on recent evidence of the utility of statins, specifically 3-hydroxy-3-methylglutaryl-coA reductase inhibitors, in the prevention and treatment of the various pulmonary diseases described above.
- 1 September 2024
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 31 (9) , 1249-1259
Open AccessThe Association between Dyslipidemia and Pulmonary Diseases
Dyslipidemia is one of the most common diseases worldwide. As a component of metabolic syndrome, the prevalence and mechanism by which dyslipidemia promotes cardiovascular diseases has been well studied, although the relationship between pulmonary diseases is not well understood. Because the lung is a respiratory organ with a large surface area and is exposed to the environment outside the body, it continuously inhales various substances. As a result, pulmonary diseases have a vast diversity, including chronic inflammatory diseases, allergic diseases, cancers, and infectious diseases. Recently, growing evidence has suggested that dyslipidemia plays a role in the pathogenesis and prognosis of various pulmonary diseases. We herein review the current understanding of the relationship between dyslipidemia and pulmonary diseases, including chronic obstructive pulmonary diseases, asthma, and lung cancer, and infectious pulmonary diseases, including community-acquired pneumonia, tuberculosis, nontuberculous mycobacterial pulmonary disease, and COVID-19. In addition, we focus on recent evidence of the utility of statins, specifically 3-hydroxy-3-methylglutaryl-coA reductase inhibitors, in the prevention and treatment of the various pulmonary diseases described above.
- Open Access
- 9 August 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (5) , 910-913
Molecular analysis of non-small cell lung cancer using a dual-targeted DNA and RNA comprehensive genomic profiling panel
- 9 August 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (5) , 910-913
Open AccessMolecular analysis of non-small cell lung cancer using a dual-targeted DNA and RNA comprehensive genomic profiling panel
- Open Access
- 16 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23827
Comprehensive metabolic modulations of sphingolipids are promising severity indicators in COVID ‐19
The COVID‐19 pandemic, caused by SARS‐CoV‐2, has had a significant worldwide impact, affecting millions of people. COVID‐19 is characterized by a heterogenous clinical phenotype, potentially involving hyperinflammation and prolonged tissue damage, although the exact underlying mechanisms are yet to be fully understood. Sphingolipid metabolites, which govern cell survival and proliferation, have emerged as key players in inflammatory signaling and cytokine responses. Given the complex metabolic pathway of sphingolipids, this study aimed to understand their potential role in the pathogenesis of COVID‐19. We conducted a comprehensive examination of sphingolipid modulations across groups classified based on disease severity, incorporating a time‐course in serum and urine samples. Several sphingolipids, including sphingosine, lactosylceramide, and hexosylceramide, emerged as promising indicators of COVID‐19 severity, as validated by correlation analyses conducted on both serum and urine samples. Other sphingolipids, such as sphingosine 1‐phosphate, ceramides, and deoxy‐dihydroceramides, decreased in both COVID‐19 patients and individuals with non‐COVID infectious diseases. This suggests that these sphingolipids are not specifically associated with COVID‐19 but rather with pathological conditions caused by infectious diseases. Our analysis of urine samples revealed elevated levels of various sphingolipids, with changes dependent on disease severity, potentially highlighting the acute kidney injury associated with COVID‐19. This study illuminates the intricate relationship between disturbed sphingolipid metabolism, COVID‐19 severity, and clinical factors. These findings provide valuable insights into the broader landscape of inflammatory diseases.
- 16 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23827
Open AccessComprehensive metabolic modulations of sphingolipids are promising severity indicators in COVID ‐19
The COVID‐19 pandemic, caused by SARS‐CoV‐2, has had a significant worldwide impact, affecting millions of people. COVID‐19 is characterized by a heterogenous clinical phenotype, potentially involving hyperinflammation and prolonged tissue damage, although the exact underlying mechanisms are yet to be fully understood. Sphingolipid metabolites, which govern cell survival and proliferation, have emerged as key players in inflammatory signaling and cytokine responses. Given the complex metabolic pathway of sphingolipids, this study aimed to understand their potential role in the pathogenesis of COVID‐19. We conducted a comprehensive examination of sphingolipid modulations across groups classified based on disease severity, incorporating a time‐course in serum and urine samples. Several sphingolipids, including sphingosine, lactosylceramide, and hexosylceramide, emerged as promising indicators of COVID‐19 severity, as validated by correlation analyses conducted on both serum and urine samples. Other sphingolipids, such as sphingosine 1‐phosphate, ceramides, and deoxy‐dihydroceramides, decreased in both COVID‐19 patients and individuals with non‐COVID infectious diseases. This suggests that these sphingolipids are not specifically associated with COVID‐19 but rather with pathological conditions caused by infectious diseases. Our analysis of urine samples revealed elevated levels of various sphingolipids, with changes dependent on disease severity, potentially highlighting the acute kidney injury associated with COVID‐19. This study illuminates the intricate relationship between disturbed sphingolipid metabolism, COVID‐19 severity, and clinical factors. These findings provide valuable insights into the broader landscape of inflammatory diseases.
- Open Access
- 7 May 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1368839
Alzheimer’s disease manifests abnormal sphingolipid metabolism
Introduction: Alzheimer’s disease (AD) is associated with disturbed metabolism, prompting investigations into specific metabolic pathways that may contribute to its pathogenesis and pathology. Sphingolipids have garnered attention due to their known physiological impact on various diseases.Methods: We conducted comprehensive profiling of sphingolipids to understand their possible role in AD. Sphingolipid levels were measured in AD brains, Cerad score B brains, and controls, as well as in induced pluripotent stem (iPS) cells (AD, PS, and control), using liquid chromatography mass spectrometry.Results: AD brains exhibited higher levels of sphingosine (Sph), total ceramide 1-phosphate (Cer1P), and total ceramide (Cer) compared to control and Cerad-B brains. Deoxy-ceramide (Deoxy-Cer) was elevated in Cerad-B and AD brains compared to controls, with increased sphingomyelin (SM) levels exclusively in Cerad-B brains. Analysis of cell lysates revealed elevated dihydroceramide (dhSph), total Cer1P, and total SM in AD and PS cells versus controls. Multivariate analysis highlighted the relevance of Sph, Cer, Cer1P, and SM in AD pathology. Machine learning identified Sph, Cer, and Cer1P as key contributors to AD.Discussion: Our findings suggest the potential importance of Sph, Cer1P, Cer, and SM in the context of AD pathology. This underscores the significance of sphingolipid metabolism in understanding and potentially targeting mechanisms underlying AD.
- 7 May 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1368839
Open AccessAlzheimer’s disease manifests abnormal sphingolipid metabolism
Introduction: Alzheimer’s disease (AD) is associated with disturbed metabolism, prompting investigations into specific metabolic pathways that may contribute to its pathogenesis and pathology. Sphingolipids have garnered attention due to their known physiological impact on various diseases.Methods: We conducted comprehensive profiling of sphingolipids to understand their possible role in AD. Sphingolipid levels were measured in AD brains, Cerad score B brains, and controls, as well as in induced pluripotent stem (iPS) cells (AD, PS, and control), using liquid chromatography mass spectrometry.Results: AD brains exhibited higher levels of sphingosine (Sph), total ceramide 1-phosphate (Cer1P), and total ceramide (Cer) compared to control and Cerad-B brains. Deoxy-ceramide (Deoxy-Cer) was elevated in Cerad-B and AD brains compared to controls, with increased sphingomyelin (SM) levels exclusively in Cerad-B brains. Analysis of cell lysates revealed elevated dihydroceramide (dhSph), total Cer1P, and total SM in AD and PS cells versus controls. Multivariate analysis highlighted the relevance of Sph, Cer, Cer1P, and SM in AD pathology. Machine learning identified Sph, Cer, and Cer1P as key contributors to AD.Discussion: Our findings suggest the potential importance of Sph, Cer1P, Cer, and SM in the context of AD pathology. This underscores the significance of sphingolipid metabolism in understanding and potentially targeting mechanisms underlying AD.
- Open Access
- 15 February 2024
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 39, e00369
Correlation between variant call accuracy and quality parameters in comprehensive cancer genomic profiling tests
- 15 February 2024
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 39, e00369
Open AccessCorrelation between variant call accuracy and quality parameters in comprehensive cancer genomic profiling tests
- 21 December 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 694, 149419
Understanding the modulations of glycero-lysophospholipids in an elastase-induced murine emphysema model
- 21 December 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 694, 149419
Understanding the modulations of glycero-lysophospholipids in an elastase-induced murine emphysema model